Ticker Hub
MBRX — AI Analysis & Sentiment
3 recent AI-generated analyses for MBRX. Sentiment and confidence insights updated continuously.
Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
Moleculin announced positive preclinical data for Annamycin in metastatic pancreatic cancer, showing increased survival and tumor reduction. This e...
Apr 23, 2026Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
Moleculin reached a key enrollment milestone in its pivotal MIRACLE trial, setting the stage for critical mid-2026 data. This progress offers upsid...
Mar 23, 2026Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
Moleculin's preliminary Phase 2B/3 MIRACLE trial for Annamycin shows a highly encouraging 40% complete remission rate in AML, significantly exceedi...
Feb 18, 2026